Drug Approval | January 24, 2024
The company has received five final approvals
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
Prasugrel tablets are indicated to reduce the rate of thrombotic CV events
Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
Phase 2 Study of MK-2060 Currently Ongoing in People with End-Stage Renal Disease Receiving Hemodialysis
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
Subscribe To Our Newsletter & Stay Updated
